Bonnot PE, et al. - Among patients with peritoneal metastases (PMs) from gastric cancer (GC) (n=277) who received treatment at 19 French centers from 1989 to 2014, researchers compared the outcomes between those who had cytoreductive surgery (CRS)-hyperthermic intraperitoneal chemotherapy (HIPEC) (n=180) vs those who had CRS alone (CRSa, n=97). As revealed in inverse probability of treatment weighting analysis, median overall survival (OS) for CRS-HIPEC and CRSa groups was 18.8 vs 12.1 months, respectively, and the rates for 3- and 5-year OS were 26.21% and 19.87% vs 10.82% and 6.43%, for the respective groups. The rates of 3- and 5-year recurrence-free survival were 20.40% and 17.05% and 5.87% and 3.76%, respectively. Without additional morbidity or mortality, OS and recurrence-free survival were improved with CRS-HIPEC vs CRSa. For strictly selected patients with limited PMs from GC, CRS-HIPEC may be a effective therapy in cases where complete CRS is possible.